A- A A+

Quantifying Gabapentin Misuse With Opioids.

Peckham AM, Sclar DA.

Prim Care Companion CNS Disord. 2019 Mar 14;21(2). pii: 18l02386. doi: 10.4088/PCC.18l02386. 

https://www.psychiatrist.com/PCC/article/Pages/2019/v21n02/18l02386.aspx

A Clinical Overview of Off-label Use of Gabapentinoid Drugs.

Goodman CW, Brett AS.

JAMA Intern Med. 2019 Mar 25. doi: 10.1001/jamainternmed.2019.0086.

Abstract

https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2728959

Gabapentin and Cancer Risk: Updated Findings from Kaiser Permanente Northern California.

Friedman GD, Achacoso N, Habel LA.

Perm J. 2019;23. pii: 18-040. doi: 10.7812/TPP/18-040.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380473/

Prescribing practice of pregabalin/gabapentin in pain therapy: an evaluation of German claim data

Viniol A, Ploner T, Hickstein L, et al

BMJ Open 2019;9:e021535. doi: 10.1136/bmjopen-2018-021535 

https://bmjopen.bmj.com/content/9/3/e021535

Gabapentinoide. Forschungsteam mahnt bei Schmerztherapie zur Vorsicht

Die Medikamente Pregabalin und Gabapentin werden zunehmend bei allgemeinen chronischen Schmerzen eingesetzt, obwohl ihre Wirksamkeit bei dieser Anwendung zweifelhaft ist. Das schließen Medizinerinnen und Mediziner aus der Analyse von Verschreibungsdaten der Krankenversicherungen. Das Team veröffentlichte seine Ergebnisse in der Fachzeitschrift „BMJ Open“. (Philipps-Universität Marburg, 05.04.2019)

https://idw-online.de/de/news713576

Pregabalin: A range of misuse-related unanswered questions.

Schifano F, Chiappini S.

CNS Neurosci Ther. 2019 Mar 4. doi: 10.1111/cns.13115.

https://onlinelibrary.wiley.com/doi/full/10.1111/cns.13115

UK. Pregabalin and gabapentin to be reclassified as Class C controlled substances

Following a public consultation and advice from the Advisory Council on the Misuse of Drugs, gabapentinoids are to be reclassified following concerns over misuse. 

The Pharmaceutical Journal, October 2018, Corrinne Burns, Vol 301, No 7918, online | DOI: 10.1211/PJ.2018.20205611 

https://www.pharmaceutical-journal.com/news-and-analysis/news/pregabalin-and-gabapentin-to-be-reclassified-as-class-c-controlled-substances/20205611.article

Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France.

Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M.

Br J Clin Pharmacol. 2019 Feb 8. doi: 10.1111/bcp.13892.

Abstract 

https://www.ncbi.nlm.nih.gov/pubmed/30737829

First case of skin allergy to pregabalin with positive patch tests.

Gómez Torrijos E, Moreno Lozano L, Extrmera Ortega AM, Gonzalez Jimenez O, Gratacós Gómez AR, Garcia Rodriguez R.

Contact Dermatitis. 2019 Feb 21. doi: 10.1111/cod.13249.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30793330

Pregabalin misuse: the next wave of prescription medication problems.

Murnion B, Conigrave KM.

Med J Aust. 2019 Feb;210(2):72-73. doi: 10.5694/mja2.12056. 

https://onlinelibrary.wiley.com/doi/full/10.5694/mja2.12056

Pregabalin misuse-related ambulance attendances in Victoria, 2012-2017: characteristics of patients and attendances.

Crossin R, Scott D, Arunogiri S, Smith K, Dietze PM, Lubman DI.

Med J Aust. 2019 Feb;210(2):75-79. doi: 10.5694/mja2.12036.

https://onlinelibrary.wiley.com/doi/full/10.5694/mja2.12036

Gabapentin Use in Acute Alcohol Withdrawal Management.

Wilming C, Alford M, Klaus L.

Fed Pract. 2018 Mar;35(3):40-46.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368058/

Einladung: Gabapentinoide in der Suchtmedizin - Webinar für Ärzte und Apotheker, Freitag, 05.04.2019 ,15:00 – 16:30 Uhr, ODER online zu jeder Zeit

(...) In diesem Webinar möchten wir uns der Thematik „Gabapentinoide in der Suchtmedizin“ widmen, welche unter substituierenden Ärzten intensiv diskutiert wird. Wir freuen uns, dass wir dafür Thorsten Kelter gewinnen konnten. Herr Kelter ist Facharzt für Neurologie und ärztlicher Leiter der Düsseldorfer Diamorphin Ambulanz. In diesem Zusammenhang wird er häufig sowohl mit dem medizinischen als auch nicht-medizinischen Konsum von Gabapentinoiden konfrontiert.

Im Mittelpunkt dieser spannenden Fortbildung stehen neben dem praktischen Vorgehen bei medizinisch indiziertem Einsatz, das Gefährdungs- und Abhängigkeitspotenzial von Gabapentinoiden im Vergleich zu anderen psychoaktiven Substanzen sowie mögliche Problemstellungen bei deren Entzug.

Seien Sie unser Gast und freuen Sie sich auf einen kurzweiligen und informativen Vortrag. (subletter.de / Hexal, 21.02.2019)

Einladung: Gabapentinoide in der Suchtmedizin - Webinar für Ärzte und Apotheker, Freitag, 05.04.2019 ,15:00 – 16:30 Uhr, ODER online zu jeder Zeit

Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility.

Nichols TA, Robert S, Taber DJ, Cluver J.

Ment Health Clin. 2019 Jan 4;9(1):1-5. doi: 10.9740/mhc.2019.01.001. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322820/

Pregabaline as a Rare Cause of Hepatotoxicity.

Düzenli T, Ata E, Kösem M, Bayram Çarli A.

Pain Med. 2017 Jul 1;18(7):1407-1408. doi: 10.1093/pm/pnw332. 

https://academic.oup.com/painmedicine/article/18/7/1407/2903880

Pregabalin-associated Discontinuation Symptoms: A Case Report.

Naveed S, Faquih AE, Chaudhary AMD.

Cureus. 2018 Oct 8;10(10):e3425. doi: 10.7759/cureus.3425.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284877/

Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report.

Kulaksızoğlu B, Kara H, Bodur B, Kuloğlu M.

Neuropsychiatr Dis Treat. 2018 Nov 9;14:3033-3035. doi: 10.2147/NDT.S179688. eCollection 2018.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233699/

Gabapentin-related suicide: Myth or fact?

Ghaly RF, Plesca A, Rana S, Candido KD, Knezevic NN.

Surg Neurol Int. 2018 Oct 23;9:210. doi: 10.4103/sni.sni_420_17. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213802/

Bilateral Serous Macular Detachment After Attempted Suicide with Pregabalin.

Tanyıldız B, Kandemir B, Mangan MS, Tangılntız A, Göktaş E, Şimşek Ş.

Turk J Ophthalmol. 2018 Oct;48(5):254-257. doi: 10.4274/tjo.70923.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216534/

Pfizer hit by UK Supreme Court ruling on Lyrica patent

Pfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to claims for hundreds of millions of pounds from the NHS. (pharmaphorum, UK, 15.11.2018)

https://pharmaphorum.com/news/pfizer-hit-by-uk-supreme-court-ruling-on-lyrica-patent/

BfArM. Gabapentin zur Behandlung der Spastik im Rahmen der Multiplen Sklerose

Bewertung der Expertengruppe off-Label im Bereich Neurologie/Psychiatrie nach §35C Absatz 1 SGB V zur Off-Label-Indikation von Gabapentin zur Behandlung der Spastik im Rahmen der Multiplen Sklerose

BfArM, November 2018

https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/BereitsZugelAM/offlabel/Bewertungen/Gabapentin.pdf?__blob=publicationFile&v=6

Acute harms associated with pregabalin misuse in Victoria: a 6-year examination of ambulance attendances

Rose Crossin, Debbie Scott, Shalini Arunogiri, Karen Smith, Paul M Dietze and Dan I Lubman

Med J Aust || doi: 10.5694/mja2.12036, Published online: 26 November 2018

https://www.mja.com.au/system/files/2018-11/MJA2_12036_Rev.pdf

Australien. Ambulance call-outs for pregabalin have spiked – here’s why

(...) Until recently, researchers and doctors did not think pregabalin was addictive. But now studies suggest pregabalin may also have an indirect effect on the brain’s reward chemical, dopamine. 

Our research, published today in the Medical Journal of Australia, shows ambulance call-outs associated with the misuse of pregabalin have increased tenfold in Victoria since 2012. This mirrors an increase in prescription rates. (The Conversation, Australien, 25.11.2018)

https://theconversation.com/ambulance-call-outs-for-pregabalin-have-spiked-heres-why-106163

Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness [Internet].

Narain T, Adcock L.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Mar 12.

https://www.ncbi.nlm.nih.gov/books/NBK531934/

UK. Pregabalin and gabapentin to be controlled as class C drugs - New controls over prescription drugs pregabalin and gabapentin following rising fatalities. 

Prescription drugs pregabalin and gabapentin are to be reclassified as class C controlled substances from next April, the government announced today.

Today’s move comes after experts highlighted rising numbers of fatalities linked to the drugs. The change means it will be illegal to possess pregabalin and gabapentin without a prescription and it will be illegal to supply or sell them to others.

The drugs, which are used to treat nerve pain, epilepsy and anxiety, can bring about an elevated mood in users but can also have serious side effects, particularly when used in combination with other drugs. (gov.uk/government, Home Office, 15.10.2018)

https://www.gov.uk/government/news/pregabalin-and-gabapentin-to-be-controlled-as-class-c-drugs

UK. Correspondence: Addendum to advice on the anticonvulsant drugs Pregabalin and Gabapentin, October 2018 

(...) Revised Section 6. Recommendations

The ACMD recommends that both Pregabalin and Gabapentin, their salts and their esters are: controlled under the Misuse of Drugs Act 1971 as Class C substances, andscheduled under the Misuse of Drugs Regulations 2001 (as amended) as Schedule 3, so as not to preclude legitimate use on prescription. (ACMD - Advisory Council on the Misuse of Drugs (gov.uk), Updated 17 October 2018)

https://www.gov.uk/government/publications/advice-on-the-anticonvulsant-drugs-pregabalin-and-gabapentin

UK. Pregabalin and gabapentin to be controlled as class C drugs 

New controls over prescription drugs pregabalin and gabapentin following rising fatalities. (Home Office and Victoria Atkins MP, UK, 15.10.2018)

https://www.gov.uk/government/news/pregabalin-and-gabapentin-to-be-controlled-as-class-c-drugs

UK. Consultation outcome: Pregabalin and gabapentin: proposal to schedule under the Misuse of Drugs Regulations 2001 

Detail of outcome

On 13 November 2017, the Home Office asked for views on options whether, and how, to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001. This followed the recommendation by the Advisory Council on the Misuse of Drugs (ACMD) that pregabalin and gabapentin should be controlled as Class C drugs under the Misuse of Drugs Act 1971 (‘the 1971 Act’) and placed in Schedule 3 to the Misuse of Drugs Regulations 2001. The consultation lasted until 22 January 2018 and was UK-wide.

Responses were accepted from members of the public, healthcare professionals, institutions, all sectors within the supply chain including the pharmaceutical industry, wholesalers, and community pharmacies in the UK.

The Home Office is grateful for the views of those who responded to the consultation. On balance, the government is of the view that option 2 – to schedule the drugs under Schedule 3 to the 2001 Regulations but without the safe custody requirements – provides appropriate and necessary safeguards while ensuring that there are not unduly onerous storage requirements for pharmacists, wholesalers and others. (Home Office, UK, 15.10.2018)

https://www.gov.uk/government/consultations/pregabalin-and-gabapentin-proposal-to-schedule-under-the-misuse-of-drugs-regulations-2001

Triphasic Waves and Encephalopathy in the Setting of Pregabalin Toxicity.

Anand P, Kaplan PW.

J Clin Neurophysiol. 2018 Sep 11. doi: 10.1097/WNP.0000000000000511. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30222638

Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?

Peckham AM, Evoy KE, Ochs L, Covvey JR.

Subst Abuse. 2018 Sep 23;12:1178221818801311. doi: 10.1177/1178221818801311. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153543/